New drug efruxifermin aims to reverse liver scarring in NASH patients
Disease control
Ongoing
This Phase 3 study tests whether efruxifermin, given as a weekly shot, is safe and can improve liver health in 700 adults with NASH/MASH (a type of fatty liver disease). Participants receive either the drug or a placebo. The study tracks side effects and measures changes in liver…
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC